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Abstract
Background: Inherited genetic factors such as E-cadherin (CDH1) promoter variants are believed
to influence the risk towards sporadic diffuse gastric cancer (DGC). Recently, a new regulatory
region essential for CDH1 transcription has been identified in CDH1 intron 2.
Methods: We genotyped all known polymorphisms located within conserved sequences of CDH1
intron 2 (rs10673765, rs9932686, rs1125557, rs9282650, rs9931853) in an Italian population
consisting of 134 DGC cases and 100 healthy controls (55 patient relatives and 45 unrelated,
matched individuals). The influence of individual variants on DGC risk was assessed using χ2-tests
and logistic regression. The relative contribution of alleles was estimated by haplotype analysis.
Results: We observed a significant (p < 0.0004) association of the CDH1 163+37235G>A variant
(rs1125557) with DGC risk. Odds ratios were 4.55 (95%CI = 2.09–9.93) and 1.38 (95%CI = 0.75–
2.55) for AA and GA carriers, respectively. When adjusted for age, sex, smoking status, alcohol
intake and H. pylori infection, the risk estimates remained largely significant for AA carriers.
Haplotype analysis suggested the 163+37235A-allele contributes to disease risk independently of
the other variants studied.
Conclusion: The CDH1 163+37235G>A polymorphism may represent a novel susceptibility
variant for sporadic DGC if confirmed in other populations. Considering the broad expression of
E-cadherin in epithelia, this exploratory study encourages further evaluation of the 163+37235A-
allele as a susceptibility variant in other carcinomas.
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Gastric cancer is a major cause of cancer-related mortality
and is usually classified into two histological types, the
intestinal and the diffuse form (Lauren classification [1]).
The general incidence rates for stomach cancer are in a
steady decline, largely due to decreasing rates of the intes-
tinal cancer-type. This falling frequency is believed to be
the result of improved nutrition and sanitary conditions.
In contrast, the incidence of diffuse gastric cancer (DGC)
alone appears more stable over the past few decades [1,2].
Such a constant rate suggests a larger contribution of
inherited genetic risk rather than environmental factors to
the diffuse form of stomach cancer.
Owing to its early development underneath the gastric
mucosal surface [3], DGC is usually diagnosed at an
advanced stage and consequently associated with a poorer
outcome [1]. Therefore, genetic DGC markers may facilitate
the identification of individuals at risk and thereby contrib-
ute to an improvement in DGC diagnosis and therapy.
On a molecular level, DGC is distinguished from the
intestinal type on the basis of its abnormal expression of
the cell-cell adhesion molecule E-cadherin [4]. E-cadherin
is the key component of the epithelial adherens junction
and as such is required for functional intercellular adhe-
sion within epithelial sheets [5]. In contrast to many other
epithelial cancers, E-cadherin is downregulated very early
during DGC development, suggesting a role in the initia-
tion of this disease [3]. Mutation and promoter hyper-
methylation of the E-cadherin gene (CDH1) are the most
consistent genetic alterations observed in sporadic DGC
[6,7]. Furthermore, CDH1 germline mutations predispose
to hereditary DGC [8] consistent with an initiating func-
tion of E-cadherin deficiency in DGC. CDH1 germline
mutations usually co-segregate with a dominant pattern
of disease among affected families, and occasionally can
be found in isolated DGC cases diagnosed at a young age
(<45 y) [9]. However, they account for only about 1% of
all DGC cases [9] and hence cannot explain the genetic
aetiology postulated to contribute to apparent sporadic
DGC cases. Genetic alterations other than CDH1 germline
mutations are therefore likely to add to the risk of devel-
oping DGC in the absence of a clear family history or a
young age at diagnosis.
Common allelic variants with a mild functional effect can
influence the risk for sporadic disease. Indeed, a single
nucleotide polymorphism (SNP) within the CDH1 pro-
moter (-160C>A) has been associated with a significantly
increased risk of sporadic DGC in certain high-incidence
populations [10-13]. Of the studied CDH1 SNPs, the -
160A promoter allele is so far the only variant implicated
in DGC risk but appears to act in combination with other
CDH1 polymorphisms [10,13].
Recently, a new CDH1 regulatory region has been
described [14]. This region is contained within CDH1
intron 2, the largest non-coding CDH1 segment (66% of
the total sequence) and has been shown to be required for
both the initiation and maintenance of transcriptional
CDH1 activity in differentiated epithelia. Importantly,
intron 2 sequences are also necessary for normal CDH1
transcription during adult life, providing the possibility
that variants within this region may affect diffuse gastric
carcinogenesis.
In this study, we genotyped all known variants located
within the conserved sequences of CDH1 intron 2 and
determined their allelic frequencies in groups of Italian
sporadic DGC cases and healthy individuals to unravel
possible associations with disease.
Methods
Patients
DNA samples were obtained from 134 DGC patients who
were natives of the District of Pesaro-Urbino, Region
Marche, Central Italy. After surgery, the DGC diagnosis
was independently confirmed by two pathologists.
Patients were clinically evaluated at the local Medical
Oncology Unit (Hospital d'Urbino), where they also com-
pleted a demographic sheet including their personal and
familial cancer history. Data were verified during inter-
views with their oncology physicians and their family his-
tory was traced back for ≥3 generations and laterally to 2nd
and 3rd degree relatives. On the basis of this evaluation,
none of the patients met the clinical criteria for known
familial cancer syndromes. The inclusion criteria for eligi-
ble patients were: Caucasian ethnicity, native of the stud-
ied geographical area and lack of family history of cancer.
The same criteria plus lack of personal history of cancer
were adopted for controls. Control DNA samples were
obtained from 55 healthy relatives, who were either unaf-
fected parents (n = 15), siblings (22) or children (18) of
the studied DGC patients. As healthy relatives were not
available for every DGC patient, DNA samples from a
group of unrelated healthy individuals (n = 45) identified
through the pool of former and current blood donors
from the Hospital d'Urbino were included yielding a total
of 100 controls. Unrelated controls were randomly
selected with frequencies matching to cases by age and
sex. The mean age of DGC patients without relatives was
54.6 y ± 11.41SD, while that of their matched controls
was 52.2 y ± 10.21SD. All subjects were interviewed about
their smoking and drinking habits. H. pylori status was
determined by pathological examination of gastric sam-
ples for cases, and by blood or breath tests for controls.
The ethical requirements were verified and approved by
the internal Ethical Committee (Hospital d'Urbino) and
all study participants gave their written informed consent.Page 2 of 9
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Conserved regions of CDH1 intron 2 (GenBank
NC_000016) were identified by retrieving corresponding
human, chimpanzee, rat and mouse sequences from the
NCBI database (NCBI, Entrez nucleotide) followed by
alignment using the NCBI server (NCBI, Basic Local Align-
ment Search Tool) and Invitrogen Vector NTI Advance™
9.0 software (Accelrys Software Inc, San Diego, USA).
Conserved regions were defined as having less than 5%
sequence variations among the different species. The con-
served regions were PCR-amplified into overlapping frag-
ments of about 200 bp size. The corresponding primers
(see Table 1 for sequences and conditions) were designed
using the GeneFisher online tool [15] and manufactured
by Sigma-Proligo (Sigma-Aldrich Corporation, St. Louis,
USA). FastStart Taq DNA Polymerase (Roche, Basel, Swit-
zerland) and PTC-200 PCR machines (MJ Research,
Waltham, USA) were used. The following polymorphisms
are located (Ensemble GenomeBrowser [16]) within the
amplified regions: 163+14184ΔAGGG (rs10673765,
located in PCR fragment C2F1), 163+14384C>T
(rs9932686, C2F2), 163+37235G>A (rs1125557, C3F2),
163+37276T>A (rs9282650, C3F2), and 163+49526C>G
(rs9931853, C4F1). The TESS online tool [17] was used to
search for putative transcription binding factor sites that
may be affected by the above variants.
Single-strand conformation polymorphism
Single-strand conformation polymorphism (SSCP) was
used to scan the conserved intron 2 region in 19 Italian
DGC patients for the presence of additional common but
population-specific polymorphisms. SSCP was performed
as described [18], with the exception that ULS™ 495 fluor-
ophore (Kreatech Biotechnology, Amsterdam, Nether-
lands) was used instead of radioactivity to label the
fragments. In brief, 1 μl PCR product was incubated with
0.2 μl dye in a 20 μl reaction. Gels were scanned using an
FX molecular imager (BioRad, Hercules, USA) at 488 nm.
Genotyping
The following restriction enzymes were used for the geno-
typing of DNA variants: 0.06 U/μl BsaXI for
163+14184ΔAGGG, 1 U/μl BanII for 163+14384C>T, 0.2
U/μl MaeIII for 163+37276T>A, and 0.4 U/μl HpaII for
163+49526C>G. All enzymes were from New England
Biolabs (Ipswich, USA) with the exception of MaeIII from
Roche (Basel, Switzerland). Reactions were incubated
overnight and fragments were separated on 4%(w/v) aga-
rose gels.
Polymorphisms 163+37235G>A and 163+37276T>A
were genotyped on a ABI Prism 7900 (Applied Biosys-
tems, Foster City, USA) using the real-time PCR-based
allelic discrimination assays from Applied Biosystems
according to the instructions provided.
Sequencing
Detected variants were verified by direct sequencing using
the USB thermosequencing kit (USB, Cleveland, USA)
and a LiCor 4000L DNA sequencer (LiCor, Lincoln,
Nebraska USA).
Table 1: PCR primers and conditions
Forward primer Reverse primer Ta* Mg++† DMSO‡
C1F1 ccgccttaaagaaactcttg accggtggcaaatactag 65°C 1.5 -
C1F2 tagaagggttgaacctgttc tcttagtccacgagaagaag 65°C 1.5 -
C1F3 taggagagcttgtaacaagc cactcggttctaccgaag 65°C 1.5 -
C2F1 tgtattagccacagagaag ctaaaactagaccacgaag 65°C 1.5 -
C2F2 gtcacaaaacagcttg ccttccttgagcaaggc 65°C 1.5 -
C3F1 ttgcctaaggccccctttttgttc gaatctgcgaagtctacatc 65°C 1.5 -
C3F2 acactagccacacatgggactcaag tgctggtgtggattcaaatgtg 65°C 1.5 -
C4F1 acctccgcctcctgggttcaagc ttcctcccgcttagtg 60°C 1.5 -
C4F2 tggccaggcctgtcttaaactc ttcttaggtccgtgggtttttacg 65°C 1.5 -
C4F3 aaagtgctgggattacaggtgtgag tcgataatcccgagaactc 55°C 1.0 +
C4F4 gaaccataggactttgactgatgg actgatggttatccgggttcccttg 65°C 1.5 -
C4F5 agctgttgagctgtcatcacaatcc gaatttcctacccgtctatggtagg 65°C 1.5 -
C5F1 tagtggggagtggggtcttagcttc tcgttcaccctcctttcttcttacc 58°C 1.5 -
C5F2 gggcatgttgaaatatacccagtc tctgagtaatagaggggtacgttgg 65°C 1.5 -
C5F3 cttgccagcgtgacagtg cgaaaccccgtggagtag 65°C 1.5 -
C5F4 caggttggggctcctcgtcatactg cttccgacgtgacttaaggaaagag 65°C 1.5 -
C5F5 gcttgtctcaactttcactgtc gaatttcctacccgtctatggtagg 65°C 1.5 -
C6F1 tggtattcaggaggatgcag acctacgatcgtaaaaagt 65°C 1.5 -
C6F2 cccatcaatgcttatttgttctt gcctgggagacggagact 65°C 1.5 -
C6F3 tgggctgtttgagttttgttc cggtgtaaaaggttcgtgac 65°C 1.5 -
*Ta annealing temperature; †Mg++-concentration is given in mM; ‡DMSO was added at 5% f.c.Page 3 of 9
(page number not for citation purposes)
BMC Cancer 2008, 8:138 http://www.biomedcentral.com/1471-2407/8/138Statistical analysis
Differential distributions among cases and controls were
assessed by the χ2-test (with df = 2 for genotypes and df =
1 for alleles). Risk was estimated by univariate analysis
and by multiple logistic regression (STATA software, Stata-
Corp LP, College Station, USA). The χ2-test (df = 2) was
also used to examine deviations from Hardy-Weinberg
equilibrium. Age differences among patients carrying dif-
ferent genotypes were calculated using a 2-tailed t-test.
Haplotype frequencies were reconstructed from unphased
genotypes and linkage disequilibrium (LD) between SNPs
was estimated using the SHEsis software platform [19,20].
Only haplotypes with a relative frequency >0.03 in either
cases or controls were included in the analysis. Global
association of haplotypes with disease was calculated by a
χ2-test (df = 7). The 163+14184ΔAGGG and
163+14384C>T variants were not included into the final
analysis as they were not informative. The association of
individual haplotypes with disease was based on 2 × 2
contingency tables in comparison to the A-A-C haplotype.
LD was expressed as r2, with r2 = 1 indicating complete LD,
r2 = 0 absence of LD, and r2 < 0.33 suggesting minimal LD.
Results
Six conserved regions with a total size of 3.2 kbp were
identified within CDH1 intron 2. Apart from the five
known polymorphisms (CDH1163+14184ΔAGGG
(rs10673765), 163+14384C>T (rs9932686),
163+37235G>A (rs1125557), 163+37276T>A
(rs9282650), and 163+49526C>G (rs9931853)), no
additional common polymorphisms specific for the Ital-
ian population under study were discovered by SSCP in
the six regions.
Using restriction fragment length polymorphism and
allelic discrimination assays, the relative frequencies of
the genotypes resulting from the five variants were deter-
mined in the DGC cases and the controls. Sequencing of
random samples confirmed the respective genotypes. All
polymorphisms were in Hardy-Weinberg equilibrium for
both cases and controls (p > 0.19). Table 2 summarises
the genotype distributions and their differences between
cases and controls.
Of the investigated variants, only the 163+37235G>A
SNP was significantly associated with disease due to an
Table 2: CDH1 intron 2 genotype distributions among DGC cases and controls
+14184ΔAGGG cases (n = 134) +14184ΔAGGG controls (n = 100) χ2-test OR (95%CI)*,† OR (95%CI)*,†
+/+ +/Δ Δ/Δ +/+ +/Δ Δ/Δ p Δ/Δ vs +/+ +/Δ vs +/+
128 4 2 96 3 1 0.947 1.50 (0.13–16.78) 1.00 (0.21–4.57)
95.5% 3% 1.5% 97% 1.5% 1.5% 14.2% 2.5%
+14384C>T cases (n = 134) +14384C>T controls (n = 100) χ2-test OR (95%CI) OR (95%CI)
CC CT TT CC CT TT p TT vs CC CT vs CC
130 2 2 98 1 1 0.895 1.51 (0.13–16.87) 1.51 (0.13–16.87)
97.0% 1.5% 1.5% 98.0% 1.0% 1.0% 12.3% 12.3%
+37235G>A cases (n = 134) +37235G>A controls (n = 100) χ2-test OR (95%CI) OR (95%CI)
GG GA AA GG GA AA p AA vs GG GA vs GG
30 56 48 37 50 13 0.0003 4.55 (2.09–9.93) 1.38 (0.75–2.55)
22.4% 41.8% 35.8% 37.0% 50.0% 13.0% 100% 40.6%
+37276T>A cases (n = 134) +37276T>A controls (n = 100) χ2-test OR (95%CI) OR (95%CI)
TT TA AA TT TA AA p AA vs TT TA vs TT
65 65 4 46 51 3 0.929 0.94 (0.20–4.42) 0.90 (0.53–1.53)
48.5% 48.5% 3.0% 46.0% 51.0% 3.0% 1.9% 1.6%
49526C>G cases (n = 134) +49526C>G controls (n = 100) χ2-test OR (95%CI) OR (95%CI)
CC CG GG CC CG GG p GG vs CC CG vs GG
34 82 18 30 58 12 0.727 1.32 (0.55–3.19) 1.25 (0.69–2.26)
25.4% 61.2% 13.4% 30.0% 58.0% 12.0% 32.2% 22.5%
*OR values are unadjusted.
†The percentage below the OR values estimates the power of association for each variant at the corresponding OR level and assuming a significance 
level of 5%.Page 4 of 9
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(56.7% vs. 38% in controls, χ2 = 16.1, p < 0.0001; see
Table 2). The 163+37235AA genotype was 2.8 times more
frequent in cases compared to controls. The correspond-
ing Odds Ratio (OR) suggested a significantly elevated
risk of developing DGC for AA carriers relative to GG car-
riers (OR = 4.55, 95%CI = 2.09–9.93, p = 0.0002, power
of association 100%; Table 2). No significant increase in
risk was apparent from carrying the GA-genotype (OR =
1.38, 95%CI = 0.75–2.55, p = 0.3, power of association
41%; Table 2). The DGC risk for AA carriers remained sig-
nificant, when ORs were adjusted for age, sex, alcohol
intake and H. pylori infection (Table 3). In smokers, how-
ever, the associated risk was only of borderline signifi-
cance (p = 0.089, Table 3). The risks associated with the
other variants studied remained non-significant following
adjustment (data not shown). No association was
observed between the 163+37235G>A SNP and age at
diagnosis (p > 0.16).
To determine whether the CDH1 163+37235A-allele con-
fers DGC risk independently or in combination with the
other intron 2 variants, haplotypes resulting from the five
polymorphisms were reconstructed and their frequencies
were estimated in the cases and controls. The two 5'-vari-
ants were not informative and were thus excluded. The
intron 2 haplotypes showed a global association with dis-
ease (df = 7, χ2 = 24.09, p < 0.002). In general, haplotypes
containing the 163+37235A-allele were more frequent in
cases compared to controls, while three of the four haplo-
types with the G-allele were more frequent among the
controls (Table 4). The strongest association with disease
was observed for the AAG and the ATC haplotypes (with
163+37235A at position 1). Conversely, the GAG and the
GTC haplotypes showed the strongest protection. Linkage
Table 3: Adjusted ORs associated with the CDH1 intron 2 163+37235G>A variant
Variable 163+37235 Cases Controls OR (95% CI)
n % n %
Age ≤ Median GG 17 20 20 34 1
GA 37 45 30 52 1.45 (0.65–3.25)
AA 29 35 8 14 4.26 (1.55–11.77)
> Median GG 13 25 17 40 1
GA 19 37 20 48 1.24 (0.48–3.24)
AA 19 37 5 12 4.97 (1.47–16.86)
Sex Female GG 13 20 20 34 1
GA 28 44 30 51 1.44 (0.60–3.42)
AA 23 36 9 15 3.93 (1.39–11.12)
Male GG 17 24 17 41 1
GA 28 40 20 49 1.40 (0.58–3.39)
AA 25 36 4 10 6.25 (1.79–21.84)
Smoking Never GG 17 24 25 42 1
GA 30 42 30 50 1.47 (0.66–3.26)
AA 25 35 5 8 7.35 (2.34–23.01)
Ever GG 13 21 12 30 1
GA 26 42 20 50 1.20 (0.45–3.19)
AA 23 37 8 20 2.65 (0.86–8.16))
Alcohol ≤ 20 g/day GG 24 26 26 40 1
GA 35 38 31 48 1.22 (0.59–2.55)
AA 34 37 8 12 4.60 (1.78–11.90)
> 20 g/day GG 6 15 11 31 1
GA 21 51 19 54 2.01 (0.63–6.55)
AA 14 34 5 15 5.13 (1.23–21.36)
H. pylori Negative GG 2 11 16 37 1
GA 22 48 22 51 3.2 (1.00–10.26)
AA 19 41 5 12 12.16 (2.98–49.64)
Positive GG 25 28 21 37 1
GA 34 39 28 49 1.02 (0.472–-.19)
AA 29 33 8 14 3.045 (1.15–8.07)Page 5 of 9
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between the investigated variants (r2 < 0.03; Table 5), sug-
gesting that the CDH1 163+37235G>A SNP may confer
an increased susceptibility towards DGC independently
of the other variants investigated.
Eighteen of the healthy controls related to the DGC
patients were children. A few of them may develop DGC
later in their life. We therefore repeated the analysis
excluding all 18 children from the controls. The associa-
tions between the 163+37235A-containing genotypes/
haplotypes with disease were similar to those obtained
without exclusion. As expected, however, all associations
were more significant and corresponding risk estimates
increased (data not shown).
Discussion
Inherited genetic risk is believed to be a crucial factor con-
tributing to the incidence of sporadic DGC. Little is
known, however, about susceptibility loci that may confer
DGC risk without evoking an apparent family history.
CDH1, coding for the epithelial adhesion molecule E-cad-
herin, is one of the few known genes to have an etiologic
role in DGC. So far, only one polymorphism located
within the CDH1 promoter has been implicated in the
sporadic DGC risk of certain populations [10-13]. In this
study, we sought to assess a possible contribution of
CDH1 intron 2 variants to disease risk, as this region has
recently been shown to be essential for normal CDH1
transcription during adult life, similar to the CDH1 pro-
moter.
Our present results suggest a role of CDH1 intron 2 alleles
in the risk of developing sporadic DGC and identify the
163+37235G>A SNP as a putative susceptibility variant.
Both individual genotype data and corresponding haplo-
type data are consistent with a contribution of the CDH1
163+37235A-allele to DGC risk that is independent of the
other four investigated CDH1 intron 2 variants.
A strength of our study is the inclusion of healthy relatives
into the control group. Unaffected relatives are expected
to share more genetic variants with their related patients
compared to unrelated, matched controls, resulting in a
reduction of background genetic noise. While the genetic
relation may decrease the significance level of an associa-
tion, the detected genetic differences are likely more
robust. Consistent with this, exclusion of relatives too
young to have disease strengthened the association of the
163+37235A-allele with DGC. For all controls, the ratio
of the relative frequencies of the A- and G-alleles (A:G)
was 0.613, which is higher than reported for other Cauca-
sian populations (0.38, GenomeBrowser [16]). However,
the A:G ratio for unrelated controls only was 0.215, sug-
gesting that the higher ratio is due to an enrichment of the
disease allele among the relatives of DGC patients as one
would expect for a high risk population. Somewhat unu-
sual was the lack of any significant LD among the SNPs
investigated. Intermarker values between the
163+37235G>A and 163+37276T>A variants were availa-
ble for other populations on the HapMap Browser [21].
Strong LD was also absent in four different ethnic groups
(r2 range = 0.12–0.52), suggesting independent segrega-
tion of these variants may be common. Together, the data
are consistent with a direct association of the
163+37235A-allele with an increased susceptibility to
DGC.
A limitation of this study is its small sample size. The
study was designed to detect at the 5% level of significance
an OR of 2.0 for relatively common variants with power
>90%. Thus, the observed lack of significant associations
may well be due to inadequate power to detect variants of
weaker effect, particularly with rarer alleles. Larger sample
sizes will be required to conclusively assess the impact of
these variants on disease risk. However, our aim was to
identify common susceptibility loci that confer a relatively
strong risk and hence might contribute to a significant
number of apparent sporadic DGC cases. Another poten-
Table 4: CDH1 intron 2 haplotype frequencies among DGA cases and controls
Case (freq)† Control (freq)† Fisher's p Pearson's p OR (95%CI)
AAC* 16.04 (0.060) 5.31 (0.027) 0.088 0.088 2.33 (0.86–6.34)
AAG 17.49 (0.065) 5.34 (0.027) 0.056 0.056 2.55 (0.95–6.83)
ATC 73.09 (0.273) 35.43 (0.177) 0.015 0.015 1.74 (1.11–2.74)
ATG 45.38 (0.169) 29.91 (0.150) 0.565 0.565 1.16 (0.70–1.92)
GAC 21.73 (0.081) 24.18 (0.121) 0.152 0.152 0.64 (0.35–1.18)
GAG 17.75 (0.066) 22.17 (0.111) 0.087 0.087 0.57 (0.30–1.09)
GTC 39.15 (0.146) 53.07 (0.265) 0.001 0.001 0.47 (0.30–0.75)
GTG 37.37 (0.139) 24.85 (0.123) 0.602 0.602 1.16 (0.67–1.99)
*Haplotype order: 163+37235G>A, 163+37276T>A, 163+49526C>G. The two 5'-variants were not included, as they did not further split up the 
haplotypes.
†Numbers refer to reconstructed haplotype numbers among cases (257) and controls (192), with each individual carrying two chromosomes. 
Relative frequencies are given in percent. Not all genotype data was included into analysis, as low frequency haplotypes were dropped.Page 6 of 9
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to LD with other disease variants not investigated here. A
candidate variant may be the CDH1 -160A-allele. Geno-
type data for the -160 SNP were available for a subgroup
of the cases studied. Preliminary analysis suggested
absence of LD between the 163+37235 and the -160 SNP
(r2 = 0.008; BH, unpublished results), consistent with an
independent contribution of the intron 2 variant to dis-
ease. This idea is supported by the consistent association
of 163+37235A-containing haplotypes with DGC (Table
4). Additionally, the observation that in mice the pro-
moter and intron 2 are both independently required for
CDH1 activity [14] is further evidence for an autonomous
role of the intron 2 variant in DGC susceptibility. Moreo-
ver, the risk associated with the intron 2 variant remained
significant following the adjustment for potential con-
founding factors, in support of a direct association. An
exception was smoking, which reduced the associated risk
to borderline significance. Of note, the risk estimates
increased in both non-smokers and H. pylori-negative
patients. While these trends may be due to the relatively
low numbers of subjects in stratified subgroups, they may
be consistent with genetic DGC risk factors being more
important in individuals not exposed to environmental
risks.
CDH1 intron 2 sequences are vital both to initiate tran-
scriptional activity and to maintain E-cadherin expression
in differentiated epithelia of mice [14]. Given the con-
served function of E-cadherin in different species, it is very
probable that intron 2 is also essential for CDH1 activity
in human epithelia. This is supported by the presence of
highly conserved regions within intron 2, suggesting that
the conserved elements may be binding sites for transcrip-
tion factors participating in CDH1 regulation. A search for
putative binding sites revealed that the CDH1 163+37235
position lies within a recognition motif of the human
nuclear factor I/X (NFIX, OMIM #164005). According to
the TESS web page [17], the 163+37235G position
(TGGCA) is the most conserved nucleotide within the
NFIX recognition sequence, suggesting the 163+37235A-
allele may alter the affinity of this transcription factor to
the cis-regulatory element. Whether NFIX indeed is able to
regulate E-cadherin expression in gastric tissue remains to
be determined. In mice, however, NFIX is essential for
embryonic development [22] and is expressed in many
adult tissues including epithelial ones [23]. Genes regu-
lated by NFIX have been identified and include repression
of pro-angiogenic PDGFA [24] and p21, where repression
surprisingly leads to growth inhibition [25]. NFIX may
also slow down cell growth via downregulation of the
adenine nucleotide translocase-2 gene (ANT2) [26]. In
addition, NFIX has been shown to confer resistance
towards transformation by nuclear but not cytoplasmic
oncogenes [27]. The reported findings are compatible
with a tumour suppressing role of NFIX, where reduced
binding of this transcription factor to its recognition
sequence may favour tumorigenic events. It is thus of
some interest that the chromosomal region 19p13.3, the
location of NFIX, appears frequently deleted in some
[28,29], however not all [30] series of gastric cancers.
To our knowledge, this is the first study to report an asso-
ciation between an intronic CDH1 variant and sporadic
cancer. Similar studies will be required to confirm an asso-
ciation with DGC in other populations/ethnicities and,
using a larger sample size, to determine whether the
163+37235A variant may also be a disease allele in
cohorts from low DGC risk regions. Furthermore, case-
control studies on other carcinoma types, including other
gastric cancer histotypes, should address whether the
intron 2 variant is specifically associated with DGC.
Regarding the CDH1 promoter SNPs, the -160A-allele has
not only been implicated in DGC in Italians [10,11], but
also in a Mexican [12] and a Japanese [13] population
(here included in disease haplotypes). Not all reports
have found significant associations, suggesting popula-
tion-specific effects or differences in study design [31,32].
To address this heterogeneity, Wang et al. have evaluated
data from 11 case-control series and concluded that the -
160A-allele is a gastric cancer susceptibility allele in Euro-
pean, but not Asian populations [33]. However, their
meta-analysis did not include very recent studies report-
ing positive associations [11-13] and therefore may
underestimate the contribution of the -160A-allele to gas-
tric cancer. Further positive associations have been
observed with sporadic carcinomas at other sites such as
prostate [34,35], urether [36], bladder [37], breast [38],
Table 5: Linkage disequilibrium between CDH1 intron 2 polymorphisms
r2 linkage disequilibrium
163+14384C>T 163+37235G>A 163+37276T>A 163+49526C>G
163+14184ΔAGGG 0.001 0.000 0.001 0.001
163+14384C>T - 0.002 0.000 0.000
163+37235G>A - - 0.028 0.000
163+37276T>A - - - 0.003Page 7 of 9
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moter variant, -347insA, has not been associated with
sporadic DGC so far, but appears to increase susceptibility
to colorectal cancer [39] and to contribute to oesopha-
geal/cardiac cancer risk [40]. Such observations imply that
functional CDH1 variants may be involved in the suscep-
tibility towards a broad range of epithelial cancers, con-
sistent with the expression pattern of E-cadherin in
tissues. It appears likely that, in many instances, CDH1
variants will require the presence of other etiologic factors
to increase disease risk, as E-cadherin deficiency is usually
associated with cancer progression rather than initiation
[41]. Furthermore, CDH1 polymorphisms might also
affect the differentiation degree of tumours; preliminary
results from our laboratory suggest an overrepresentation
of specific CDH1 haplotypes in poorly differentiated lung
carcinomas (Emily Wilson, HSc-thesis). Therefore, the
role of the intronic CDH1 163+37235A variant as a dis-
ease allele may not be limited to sporadic DGC risk.
Conclusion
We report the identification of a new putative susceptibil-
ity variant for DGC located within conserved sequences of
CDH1 regulatory intron 2. Both individual genotype and
haplotype data suggest a contribution of the CDH1
163+37235A-allele to sporadic DGC risk that is inde-
pendent of other CDH1 variants within conserved intron
2 regions. A larger confirmatory study involving other
populations and including complete CDH1 haplotypes
will be required to assess the population-specificity and
the relative contribution of the 163+37235A-allele to dis-
ease. The establishment of heritable DGC risk factors will
be helpful particularly with respect to the difficult and
often delayed diagnosis of diffuse-type stomach cancer.
Given the universal expression of E-cadherin in epithelial
tissues, this exploratory study may also provide a basis to
investigate the role of the CDH1 163+37235G>A SNP in
the incidence and progression of tumours other than
DGC.
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